Maze Therapeutics (MAZE) Cash from Financing Activities (2024 - 2026)

Maze Therapeutics has reported Cash from Financing Activities for 3 years, with the latest figure at $42.4 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 66.75% year-over-year to $42.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.3 million (down 2.72% YoY) and the FY2025 annual result came in at $275.3 million, up 196.55% from the prior year.
• Cash from Financing Activities advanced to $42.4 million in Q1 2026 per MAZE's latest filing, from $3.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $143.8 million in Q3 2025 and troughed at -$2.2 million in Q3 2024.
• A 3-year average of $45.6 million and a median of $24.6 million in 2024 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 6786.37% in 2025, down 94.89% in 2025.
• Over 3 years, Cash from Financing Activities stood at $70.3 million in 2024, then plunged by 94.89% to $3.6 million in 2025, then jumped by 1079.86% to $42.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $42.4 million, $3.6 million, and $143.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.